Close

Driving Innovation and Job Growth Through the Life Sciences Industry

May 25 2011
Representatives of the bioscience industry testified before the U.S. Congress Joint Economic Committee today, as part of a hearing entitled Driving Innovation and Job Growth through the Life Sciences Industry.

BIO Urges Congress to Reauthorize Pendemic and All-Hazards Preparedness Act

May 17 2011
In testimony before the Senate Health, Education, Labor and Pensions Committee, BIO urged lawmakers to reauthorize the Pandemic and All-Hazards Preparedness Act and suggested that changes be made to encourage more industry participation in the development of medical countermeasures. Greater transparency and clarity in the medical countermeasure market establishment, the contracting administration process, and in advanced research and development activities is essential.

BIO Requests for FY 2012 Energy and Water Appropriations Act

May 17 2011
BIO encourages Congress to support advanced biofuels and biobased products programs and initiatives during consideration of the Fiscal Year 2012 Energy & Water Appropriations bill. Industrial biotechnology is the key enabling technology that is causing a dramatic paradigm shift in the production of fuels and chemicals. By building modern biorefineries and using industrial biotechnology our nation could significantly reduce its dependence on foreign sources of oil.

Biofuels: Congress Should Maintain Renewable Fuel Standard, BIO and Other Groups Urge (May 17, 2011)

May 17 2011
The federal Renewable Fuel Standard provides the stable policy essential to attracting private investment to the development of advanced biofuels, argue BIO and other biofuel advocacy groups in a letter to Congressional leaders.

BIO Commends Department of Commerce for Promoting Robust Intellectual Property Standards and Policies Abroad

May 13 2011
BIO joined the Pharmaceutical Research and Manufacturers of America (PhRMA) in a letter commending Department of Commerce Secretary Gary Locke for his leadership in promoting robust intellectual property standards and policies. The letter commends the United States Patent Office (PTO) for their engagement at the World Intellectual Property Organization (WIPO) resisting calls to commence negotiations on ill-advised and harmful changes to the global patent system relating to "genetic resources" and "traditional knowledge."

BIO Requests for FY 2012 Agriculture, Rural Development, FDA and Related Agencies Appropriations Act

May 12 2011
BIO respectfully supports the Administration's request for a total of $2.744 billion in budget authority for the FDA and support robust funding for key programs within the U.S. Department of Agriculture.

BIO Urges Congress to Reauthorize Pendemic and All-Hazards Preparedness Act

May 11 2011
In testimony before the Senate Health, Education, Labor and Pensions Committee, BIO urged lawmakers to reauthorize the Pandemic and All-Hazards Preparedness Act.

Dr. Stephen Sherwin, BIO Chairman and Chairman & Co-founder of Ceregene, Addresses Attendees at BIO International Convention

May 5 2011

...

BIO's Comments on the Internal Revenue Service's (IRS) Proposed Guidance Regarding the Branded Prescription Drug Fee

Apr 29 2011
BIO submitted comments in advance of the May preliminary assessment to ensure that the annual branded prescription drug fee is implemented in a manner that ensures fair apportionment of the fee, adherence to the statue, and also recognizes the practical realities of assembling and verifying the data necessary to complete the task.

BIO Statement for the Institute of Medicine Committee on Pediatric Studies Conducted under BPCA and PREA

Apr 28 2011
Dr. Ron Portman, BMS, Chair of BIO's Pediatrics Committee, presented on behalf of BIO at an Institute of Medicine (IOM) meeting on pediatric studies conducted under the Best Pharmaceuticals for Children Act and Pediatrics Research Equity Act (BPCA/PREA). Dr. Portman delivered a statement on the importance of BPCA/PREA, its value for the research and development of medicines for children, and responded to questions from the committee. This meeting was part of a series held at IOM in response to an FDA request for a study on BPCA/PREA. IOM is expected to issue a report on the findings of the committee.